Product Wiki · Recalls · EU Safety Gate (RAPEX)

Lightening Beauty Cream — recall A12/1550/17

EU Safety Gate (RAPEX) · Finland · 2017-11-10 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/1550/17
Date of alert
2017-11-10
Country / jurisdiction
Finland
Risk level
Serious risk
Risk type
Chemical
Brand
Caro White
Product category
Cosmetics
Product type
Skin lightening product
Reported risk: Tuote sisältää hydrokinonia (2 painoprosenttia ainesosaluettelon mukaan). Hydrokinoni voi aiheuttaa ihon ärsytystä ja ihottumaa. Tuote ei täytä kosmetiikka-asetuksen vaatimuksia.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Distributor
Category of measure
Ban on the marketing of the product and any accompanying measures
Date of entry into force
21/06/2017
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Lightening Beauty Cream

Risk Description (original English): The product contains hydroquinone (2% by weight according to the list of ingredients). Hydroquinone can cause skin irritation and dermatitis. The product does not comply with the Cosmetic Products Regulation.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/279395

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.